Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gleevec and Taxotere in Recurrent Non-Small Cell Lung Cancer
NCT00222144Phase 2Completed
- Sponsor
- University of Kansas
- Start
- Sep 2004
- Primary completion
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in non-small cell lung cancer (NSCLC), sponsored by University of Kansas. Primary endpoint: Response rate. Started Sep 2004; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00222144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00222144.